albuterol has been researched along with Muscular Dystrophy, Facioscapulohumeral in 6 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Muscular Dystrophy, Facioscapulohumeral: An autosomal dominant degenerative muscle disease characterized by slowly progressive weakness of the muscles of the face, upper-arm, and shoulder girdle. The onset of symptoms usually occurs in the first or second decade of life. Affected individuals usually present with impairment of upper extremity elevation. This tends to be followed by facial weakness, primarily involving the orbicularis oris and orbicularis oculi muscles. (Neuromuscul Disord 1997;7(1):55-62; Adams et al., Principles of Neurology, 6th ed, p1420)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pain and fatigue are important features in FSHD." | 6.73 | Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. ( Bleijenberg, G; Hendriks, JC; Kalkman, JS; Lindeman, E; Padberg, GW; van der Kooi, EL; van Engelen, BG, 2007) |
| "Albuterol was well tolerated; side effects included cramps, tremors, insomnia, and nervousness." | 6.70 | Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. ( Griggs, RC; King, WM; Kissel, JT; McDermott, MP; Mendell, JR; Pandya, S; Tawil, R, 2001) |
| "Salbutamol (sustained released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off)." | 2.74 | Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial. ( Attarian, S; Desnuelle, C; Doppler, V; Eymard, B; Hammouda, EH; Hogrel, JY; Lacomblez, L; Laforêt, P; Ollivier, G; Payan, CA; Pouget, J, 2009) |
| "Pain and fatigue are important features in FSHD." | 2.73 | Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. ( Bleijenberg, G; Hendriks, JC; Kalkman, JS; Lindeman, E; Padberg, GW; van der Kooi, EL; van Engelen, BG, 2007) |
| "In patients with facioscapulohumeral muscular dystrophy (FSHD) albuterol may exert anabolic effects." | 2.71 | Strength training and albuterol in facioscapulohumeral muscular dystrophy. ( Hendriks, JC; Lindeman, E; Padberg, GW; van Asseldonk, RJ; van der Kooi, EL; van der Maarel, SM; Vogels, OJ; Wohlgemuth, M, 2004) |
| "Albuterol was well tolerated; side effects included cramps, tremors, insomnia, and nervousness." | 2.70 | Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. ( Griggs, RC; King, WM; Kissel, JT; McDermott, MP; Mendell, JR; Pandya, S; Tawil, R, 2001) |
| "Creatine has been used as a muscle performance enhancer by athletes and it might be helpful in muscular dystrophies including facioscapulohumeral muscular dystrophy." | 2.42 | Drug treatment for facioscapulohumeral muscular dystrophy. ( Rose, MR; Tawil, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Payan, CA | 1 |
| Hogrel, JY | 1 |
| Hammouda, EH | 1 |
| Lacomblez, L | 1 |
| Ollivier, G | 1 |
| Doppler, V | 1 |
| Eymard, B | 1 |
| Attarian, S | 1 |
| Pouget, J | 1 |
| Desnuelle, C | 1 |
| Laforêt, P | 1 |
| Rose, MR | 1 |
| Tawil, R | 2 |
| van der Kooi, EL | 2 |
| Vogels, OJ | 1 |
| van Asseldonk, RJ | 1 |
| Lindeman, E | 2 |
| Hendriks, JC | 2 |
| Wohlgemuth, M | 1 |
| van der Maarel, SM | 1 |
| Padberg, GW | 2 |
| Kalkman, JS | 1 |
| van Engelen, BG | 1 |
| Bleijenberg, G | 1 |
| Nakagawa, M | 1 |
| Higuchi, I | 1 |
| Kissel, JT | 1 |
| McDermott, MP | 1 |
| Mendell, JR | 1 |
| King, WM | 1 |
| Pandya, S | 1 |
| Griggs, RC | 1 |
2 reviews available for albuterol and Muscular Dystrophy, Facioscapulohumeral
| Article | Year |
|---|---|
Drug treatment for facioscapulohumeral muscular dystrophy.
Topics: Adrenergic beta-Agonists; Albuterol; Creatine; Humans; Muscular Dystrophy, Facioscapulohumeral; Rand | 2004 |
[Facioscapulohumeral muscular dystrophy].
Topics: Adrenergic beta-Agonists; Albuterol; Chromosomes, Human, Pair 4; Deoxyribonucleases, Type II Site-Sp | 2001 |
4 trials available for albuterol and Muscular Dystrophy, Facioscapulohumeral
| Article | Year |
|---|---|
Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Blood Pressure; Delayed-Action Preparations; | 2009 |
Strength training and albuterol in facioscapulohumeral muscular dystrophy.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Ankle Joint; Combined Modality Therapy; Delayed-Action P | 2004 |
Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Combined Modality Therapy; Double-Blind Method; Exercise | 2007 |
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Body Mass Index; Double-Blind Method; Female; Hand Stren | 2001 |